538
A. Gini, O. G. Mancheño
Account
Synlett
in Organic Synthesis: Novel Strategies in Synthesis; Feuer, H., Ed.;
John Wiley and Sons: Hoboken, NJ, 2008, 2nd ed. 129. See also:
(d) Cardona, F.; Goti, A. Angew. Chem. Int. Ed. 2005, 44, 7832;
and references cited therein.
Dannenberg, J. J.; Dapprich, S.; Daniels, A. D.; Farkas, Ö.;
Foresman, J. B.; Ortiz, J. V.; Cioslowski, J.; Fox, D. J. Gaussian09
(Revision B.01); Gaussian Inc: Wallingford CT, 2010.
(29) (a) Benfatti, F.; Capdevila, M. G.; Zoli, L.; Benedetto, E.; Cozzi, P.
G. Chem. Commun. (Cambridge) 2009, 5919. (b) Ho, X.-H.; Mho,
S.-i.; Kang, H.; Jang, H.-Y. Eur. J. Org. Chem. 2010, 4436.
(c) Zhang, B.; Cuia, Y.; Jiao, N. Chem. Commun. 2012, 48, 4498.
(d) Schweitzer-Chaput, B.; Sud, A.; Pint, R.; Dehn, S.; Schulze, P.;
Klussmann, M. Angew. Chem. Int. Ed. 2013, 52, 13228.
(e) Pandey, G.; Jadhav, D.; Tiwari, S. K.; Singh, B. Adv. Synth.
Catal. 2014, 356, 2813.
(21) For stable N-protected nitrones, such as benzyl, allyl, or glycosyl
derivatives, see: (a) Confalone, P. N.; Pizzolato, G.; Lollar-Confa-
lone, D.; Uskokovic, M. R. J. Am. Chem. Soc. 1980, 102, 1954.
(b) Vaseila, A.; Voeffray, R. Helv. Chim. Acta 1982, 65, 1953.
(c) Cicchi, S.; Marradi, M.; Corsi, M.; Faggi, C.; Goti, A. Eur. J. Org.
Chem. 2003, 4152. (d) Ben Ayed, K.; Beauchard, A.; Poisson, J.-F.;
Py, S.; Laurent, M. Y.; Martel, A.; Ammar, H.; Abid, S.; Dujardin,
G. Eur. J. Org. Chem. 2014, 2924.
(22) For the use of α-sulfonyl N-(alkoxycarbonyl)hydroxylamine pre-
cursors, see: (a) Guinchard, X.; Vallée, Y.; Denis, J.-N. Org. Lett.
2005, 7, 5147. (b) Gioia, C.; Fini, F.; Mazzanti, A.; Bernardi, L.;
Ricci, A. J. Am. Chem. Soc. 2009, 131, 9614. For other in-situ
approaches, see: (c) Partridge, K. M.; Anzovino, M. E.; Yoon, T. P.
J. Am. Chem. Soc. 2008, 130, 2920. (d) Hussain, S. A.; Sharma, A.
H.; Perkins, M. J.; Griller, D. J. Chem. Soc., Chem. Commun. 1979,
289.
(30) Trumbull, K. A.; Branchaud, B. P. Bioorg. Med. Chem. Lett. 2005,
15, 5544.
(31) Pintér, Á.; Klussmann, M. Adv. Synth. Catal. 2012, 354, 701.
(32) For example, see: (a) Akhavan-Tafti, H.; De Silva, R.; Sandison,
M.; Handley, R. US20030232405, 2003. (b) Chen, W.; Xie, Z.;
Zheng, H.; Lou, H.; Liu, L. Org. Lett. 2014, 16, 5988.
(c) Muramatsu, W. Nakano K. 2015, 17, 1549. For the alternative
use of a strong base, see: (d) Sha, S. C.; Zhang, J.; Carroll, P. J.;
Walsh, P. J. J. Am. Chem. Soc. 2013, 135, 17602.
(23) For examples of the in-situ formation of stable nitrones, see ref.
(33) For some examples implying a multistep approach, see:
21a. For
a
recent photocatalytic oxidative approach, see:
(a) Barton, D. H. R.; Bould, L.; Clive, D. L. J.; Magnus, P. D.; Hase,
T. J. Chem. Soc. C 1971, 2204. (b) Jones, G. W.; Chang, K. T.;
Shechter, H. J. Am. Chem. Soc. 1979, 101, 3906. (c) Lapin, S. C.;
Schuster, G. B. J. Am. Chem. Soc. 1985, 107, 4243.
(a) Hou, H.; Zhu, S.; Pan, F.; Rueping, M. Org. Lett. 2014, 16,
2872. See also: (b) Morita, N.; Kono, R.; Fukui, K.; Miyazawa, A.;
Masu, H.; Azumaya, I.; Ban, S.; Hashimoto, Y.; Okamoto, I.;
Tamura, O. J. Org. Chem. 2015, 80, 4797. See also refs. 19 and 20.
(24) Vaalizadeh, H.; Dinparast, L. Heteroat. Chem. 2009, 20, 177; and
references cited therein.
(34) For an example of the undesired oxidation of diazomethane
derivatives to ketones, see: Aoyama, T.; Shioiri, T. Tetrahedron
Lett. 1986, 27, 2005.
(25) For an example of the addition of hydroxyl radicals to activated
olefins, see: (a) Grant, R. D.; Rizzardo, E.; Solomon, D. H. J. Chem.
Soc., Perkin Trans. 2 1985, 379. For related additions with
TEMPO, see: (b) Babiarz, J. E.; Cunkle, G. T.; DeBellis, A. D.;
Eveland, D.; Pastor, S. D.; Shum, P. J. Org. Chem. 2002, 67, 6831.
(c) Coseri, S.; Ingold, K. U. Org. Lett. 2004, 6, 1641. (d) Kang, Y.-
W.; Choi, Y.-J.; Jang, H.-Y. Org. Lett. 2014, 16, 4842.
(26) König, B.; Pitsch, W.; Kleon, M.; Vasold, R.; Prall, M.; Schreiner,
P. R. J. Org. Chem. 2001, 66, 1742.
(27) For an example of the nucleophilic addition of secondary
hydroxylamines to Michael acceptors, such as DMAD, see:
Crescenzi, B.; Kinzel, O.; Muraglia, E.; Orvieto, F.; Pescatore, G.;
Rowley, M.; Summa, V. WO2004058756, 2004.
(28) Calculated relative enthalpy profiles (kcal/mol) by DFT in the
gas phase (B2PLYP-D3/def2-TZVP//BP86-D3/def2-TZVP). The
calculations were performed using Turbomole 6.5 within
Gaussian basis sets. For an article on Turbomole, see: (a) Furche,
F.; Ahlrichs, R.; Hättig, C.; Klopper, W.; Sierka, M.; Weigend, F.
WIREs Comput. Mol. Sci. 2014, 4, 91. Gaussian software:
(b) Frisch, M. J.; Trucks, G. W.; Schlegel, H. B.; Scuseria, G. E.;
Robb, M. A.; Cheeseman, J. R.; Scalmani, G.; Barone, V.;
Mennucci, B.; Petersson, G. A.; Nakatsuji, H.; Caricato, M.; Li, X.;
Hratchian, H. P.; Izmaylov, A. F.; Bloino, J.; Zheng, G.;
Sonnenberg, J. L.; Hada, M.; Ehara, M.; Toyota, K.; Fukuda, R.;
Hasegawa, J.; Ishida, M.; Nakajima, T.; Honda, Y.; Kitao, O.;
Nakai, H.; Vreven, T.; Montgomery, J. A. Jr.; Peralta, J. E.; Ogliaro,
F.; Bearpark, M.; Heyd, J. J.; Brothers, E.; Kudin, K. N.; Staroverov,
V. N.; Kobayashi, R.; Normand, J.; Rhaghavachari, K.; Rendell, A.;
Burant, J. C.; Iyengar, S. S.; Tomasi, J.; Cossi, M.; Rega, N.; Millam,
J. M.; Klene, M.; Knox, J. E.; Cross, J. B.; Bakken, V.; Adamo, C.;
Jaramillo, J.; Gomperts, R.; Stratmann, R. E.; Yazyev, O.; Austin,
A. J.; Cammi, R.; Pomelli, C.; Ochterski, J. W.; Martin, R. L.;
Morokuma, K.; Zakrzewski, V. G.; Voth, G. A.; Salvador, P.;
(35) (a) Lappert, M. F.; Lorberth, J. Chem. Commun. 1967, 836.
(b) Seyferth, D.; Dow, A. W.; Menzel, H.; Flood, T. C. J. Am. Chem.
Soc. 1968, 90, 1080. (c) Seyferth, D.; Menzel, H.; Dow, A. W.;
Flood, T. C. J. Organomet. Chem. 1972, 44, 279.
(36) For examples of carbon-hydrogen methylations with TMSCHN2,
see: (a) Aoyama, T.; Shioiri, T. Synthesis 1988, 228. (b) Maruoka,
K.; Concepcion, A. B.; Yamamoto, H. Synthesis 1994, 1283. For
examples of methylenation-type reactions, see: (c) Lebel, H.;
Paquet, V.; Proulx, C. Angew. Chem. Int. Ed. 2001, 40, 2887.
(d) Dabrowski, J. A.; Moebius, D. C.; Wommack, A. J.;
Kornahrens, A. F.; Kingsbury, J. S. Org. Lett. 2010, 12, 3598.
(37) For example, see: (a) Hoshimoto, N.; Aoyama, T.; Shioiri, T. Tet-
rahedron Lett. 1980, 21, 46199. (b) Cesar, I.; Dolenc, M. S. Tetra-
hedron Lett. 2001, 42, 7099; and references cited therein.
(38) For some examples of transformations with TMSCHN2, see:
(a) Aoyama, T.; Shioiri, T. Tetrahedron Lett. 1990, 31, 5507.
(b) Kühnel, E.; Laffan, D. D. P.; Lloyd-Jones, G. C.; Martinez del
Campo, T.; Shepperson, I. R.; Slaughter, J. L. Angew. Chem. Int. Ed.
2007, 46, 7075. (c) Francais, A.; Leyva-Pérez, A.; Etxebarria-
Jardi, G.; Pena, J.; Ley, S. V. Chem. Eur. J. 2011, 17, 329. (d) Cheng,
J.; Qi, X.; Li, M.; Chen, P.; Liu, G. J. Am. Chem. Soc. 2015, 137,
2480.
(39) (a) Doyle, M. P.; Tamblyn, W. H.; Bagheri, V. J. Org. Chem. 1981,
46, 5094. (b) Zhao, X.; Zhang, Y.; Wang, J. Chem. Commun. 2012,
48, 10162; and references cited therein.
(40) Salomon, R. G.; Kochi, J. K. J. Am. Chem. Soc. 1973, 95, 3300.
(41) Okuma, K.; Nojima, A.; Matsunaga, N.; Shioji, K. Org. Lett. 2009,
11, 169.
(42) For some examples of bioactive derivatives, see: (a) Bischoff, S.;
Vassout, A.; Delini-Stula, A.; Waldmeier, P. Pharmacopsychiatry
1986, 19, 306. (b) Michael-Titus, A.; Costentine, J. Pain 1987, 31,
391. (c) Bougerolle, A. M.; Dordain, G.; Berger, J. A.; Eschalier, A.
Life Sci. 1992, 50, 161. (d) Möller, H.-J.; Volz, H. P.; Reimann, L.
W.; Stoll, K.-D. J. Clin. Psychopharmacol. 2001, 21, 59. (e) Kalis,
M. M.; Huff, N. A. Clin. Ther. 2001, 23, 680. (f) Fernández, B.;
© Georg Thieme Verlag Stuttgart · New York — Synlett 2016, 2, 526–539